医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Uptick in M&A Activity and Investor Cash Expected to Re-Invigorate Pharma and Biotech in 2018, Says EP Vantage

2017年12月06日 PM11:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & TOKYO & SAN FRANCISCO

The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong. According to EP Vantage, the editorial arm of Evaluate Ltd., the current business friendly stance at the FDA is unlikely to change next year, while M&A could see an uptick, driven by big pharma and big biotech’s need to re-stock pipelines and U.S. tax reforms.

The coming year will also test the commercial expectations that have been hung on novel therapies like CAR-T and gene therapy, which are being launched into increasingly cost-sensitive markets. Important clinical read-outs from the field of immuno-oncology, where asset values remain very high, will be closely watched – all of which will help set the tone for investors throughout the year.

“Venture capital funds are very well stocked going into 2018, and both public and private investors look set to remain supportive of innovative, early-stage drug developers,” says Amy Brown, report author. “However there is evidence that expectations have got ahead of themselves in certain areas – particularly in immuno-oncology. To keep investors on side next year the industry needs to deliver some big pipeline wins, and important new drug launches need to perform.”

“Pharma & Biotech 2018 Preview”- Analysis Highlights:

  • Gilead’s new HIV triplet is the biggest potential new drug launch of 2018, with 2022 sales seen reaching $5bn
  • Abbvie’s Humira will be biggest selling drug in 2018, with global sales topping $20bn
  • Merck’s Keytruda will add the most new sales next year, $2.3bn
  • M&A activity expected to climb after slow 2017 – US tax reform could be a deciding factor for big deals
  • Another big year predicted for venture financing, as crossover funds return and push 2017 towards a record
  • IPO window expected to remain open to cashed-up private companies
  • Another strong year expected for licensing transactions in 2018, with a pick-up in activity in 2017 set to continue
  • Focus on immuno-oncology set to continue with new checkpoint targets moving through the clinic
  • Drug pricing debate in US expected to ease, but keep an eye on the states

The report can be downloaded at http://www.evaluategroup.com/PharmaBiotech2018Preview.

###

About Evaluate
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epvantage. On Instagram: Evaluateltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171206005686/en/

CONTACT

Evaluate and EP Vantage (for U.S. media)
Christine Lindgren
+1
617-866-3906
christine.lindgren@evaluategroup.com
or
Instinctif
Partners (for non-U.S. media)

Gemma Harris/Melanie Toyne Sewell
+44
(0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗